Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Dee Gor"'
Autor:
Jules Hernández-Sánchez, Louise Harlow, Colin Church, Sean Gaine, Emily Knightbridge, Kate Bunclark, Dee Gor, Alun Bedding, Nicholas Morrell, Paul Corris, Mark Toshner
Publikováno v:
Pulmonary Circulation, Vol 8 (2017)
Our aim is to assess the safety and potential efficacy of a novel treatment paradigm in pulmonary arterial hypertension (PAH), immunomodulation by blocking interleukin-6 (IL6) signaling with the IL6 receptor antagonist, tocilizumab. Inflammation and
Externí odkaz:
https://doaj.org/article/2ade388d719b431ea6ac340587ccef6f
Autor:
Jules Hernández-Sánchez, David G. Kiely, J. Simon R. Gibbs, Joanna Pepke-Zaba, Christopher J. Rhodes, Brian Y.H. Lam, Luke Howard, Richard C. Trembath, Tae-Hwi Schwantes-An, Mark Toshner, John G Coghlan, Paul A. Corris, Amit Arora, Katie A. Lutz, Emily Knightbridge, Colin Church, Stefan Gräf, James Liley, Ken Batai, Marc Humbert, Ankit A. Desai, Louise Harlow, S. John Wort, Sean Gaine, Martin R. Wilkins, William C. Nichols, Rowena Jones, Sofia S Villar Moreschi, Jason H. Karnes, Rick A. Kittles, Lars Harbaum, Dee Gor, Florent Soubrier, Nicholas W. Morrell, Jay Suntharalingam, Michael W. Pauciulo
Publikováno v:
2022, ' Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension ', The European respiratory journal, vol. 59, no. 3, 2002463 . https://doi.org/10.1183/13993003.02463-2020
BackgroundInflammation and dysregulated immunity are important in the development of pulmonary arterial hypertension (PAH). Compelling preclinical data supports the therapeutic blockade of interleukin-6 (IL-6) signalling.MethodsWe conducted a phase 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1669f2f7075fc94c5d8cdd8d56ad4951
https://kclpure.kcl.ac.uk/ws/files/170413390/Mendelian_randomisation_and_experimental_TOSHNER_Published_online_10_Mar_22_GOLD_VoR_CC_BY_.pdf
https://kclpure.kcl.ac.uk/ws/files/170413390/Mendelian_randomisation_and_experimental_TOSHNER_Published_online_10_Mar_22_GOLD_VoR_CC_BY_.pdf
Autor:
Colin Church, Mark Toshner, Jules Hernández-Sánchez, Emily Knightbridge, Nicholas W. Morrell, Paul A. Corris, Alun Bedding, Dee Gor, Louise Harlow, Sean Gaine, Kate Bunclark
Publikováno v:
Pulmonary Circulation, Vol 8 (2017)
Pulmonary Circulation
Pulmonary Circulation
Our aim is to assess the safety and potential efficacy of a novel treatment paradigm in pulmonary arterial hypertension (PAH), immunomodulation by blocking interleukin-6 (IL6) signaling with the IL6 receptor antagonist, tocilizumab. Inflammation and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01335426d77e358bd7b63044e81829c3
https://doaj.org/article/2ade388d719b431ea6ac340587ccef6f
https://doaj.org/article/2ade388d719b431ea6ac340587ccef6f
Publikováno v:
Respiratory Medicine. 100(7):1152-1162
Summary Objectives This multicentre, parallel group, double-blind, double-dummy, randomised 24-week study was designed to compare the efficacy of salmeterol/fluticasone propionate combination (SFC) 50/250μg one inhalation twice daily (bid) with form
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2155cca4398ad60d404d299b5ccf9dc
Autor:
Michael Lundgren, Björn Tilling, Dee Gor, Sverker Jern, Lars-Erik Adolfsson, Christina Tyren, Alex Godwood
Publikováno v:
Clinical Drug Investigation. 25:231-241
The incidence of asthma exacerbations in patients receiving salmeterol/fluticasone propionate (Seretidetrade mark or Advair((R))) is low. However, when asthma control deteriorates, clinicians may instruct patients to double the dose of their inhaled
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b76c1b546c3091ec431f7e33a794002
https://doi.org/10.2165/00044011-200525040-00002
https://doi.org/10.2165/00044011-200525040-00002
Publikováno v:
International Congress Series. 1219:879-886
Various phenotypic methods have been used to monitor viral susceptibility to anti-viral agents in the management of virus diseases. Confirmation of resistance generally requires genotyping of the inhibitor target gene(s) and identification of mutatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6f097984274f555f60cc05e609e71ccd
https://doi.org/10.1016/s0531-5131(01)00656-2
https://doi.org/10.1016/s0531-5131(01)00656-2